PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 15, 2026Future Oncology0 citations

The integrated 31-gene expression profile test identifies low-risk patients with cutaneous melanoma who can forego the SLNB procedure: results from a prospective, multicenter trial

View Full Paper
TBTimothy L. BeardJGJ. Michael GuentherSLStanley P. Leong

Key Points

  • The study aimed to determine if a gene expression profile can predict SLN positivity in melanoma patients.
  • Conducted a multicenter prospective trial
  • Evaluated 31-gene expression profile test in melanoma patients
  • Assessed SLN positivity and recurrence-free survival (RFS) outcomes
  • The gene expression profile test accurately predicted SLN positivity
  • Patients who avoided SLNB had high recurrence-free survival (RFS)
  • Identified a subset of low-risk melanoma patients

Abstract

In this multi-center prospective study, the i31-SLNB accurately predicted SLN positivity, and patients who avoided SLNB based on i31-SLNB results had high RFS. Thus, the i31-SLNB identifies low-risk patients who may consider foregoing the SLNB procedure.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Beard et al. (2026) studied this question.

synapsesocial.com/papers/69b5ff5c83145bc643d1bbf4https://doi.org/10.1080/14796694.2026.2640227
Ask AI
Helpful
Bookmark
Share
View Full Paper